EKSO vs GENE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EKSO is a Hold and GENE is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EKSO’s FA Score shows that 1 FA rating(s) are green whileGENE’s FA Score has 0 green FA rating(s).
- EKSO’s FA Score: 1 green, 4 red.
- GENE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EKSO’s TA Score shows that 4 TA indicator(s) are bullish.
- EKSO’s TA Score: 4 bullish, 5 bearish.
Price Growth
EKSO (@Medical Specialties) experienced а -5.14% price change this week, while GENE (@Medical Specialties) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.14%. For the same industry, the average monthly price growth was +0.91%, and the average quarterly price growth was -2.33%.
Reported Earning Dates
EKSO is expected to report earnings on Feb 27, 2025.
GENE is expected to report earnings on Feb 28, 2024.
Industries' Descriptions
@Medical Specialties (+3.14% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| EKSO | GENE | EKSO / GENE | |
| Capitalization | 24.3M | 10.5M | 231% |
| EBITDA | -13.2M | -12.07M | 109% |
| Gain YTD | -71.200 | -68.125 | 105% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 18.3M | 8.49M | 216% |
| Total Cash | 8.64M | 3.73M | 232% |
| Total Debt | 7.17M | 382K | 1,876% |
EKSO | GENE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 43 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 91 | 87 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EKSO's Valuation (31) in the Medical Specialties industry is in the same range as GENE (43) in the Biotechnology industry. This means that EKSO’s stock grew similarly to GENE’s over the last 12 months.
EKSO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as GENE (100) in the Biotechnology industry. This means that EKSO’s stock grew similarly to GENE’s over the last 12 months.
EKSO's SMR Rating (98) in the Medical Specialties industry is in the same range as GENE (99) in the Biotechnology industry. This means that EKSO’s stock grew similarly to GENE’s over the last 12 months.
GENE's Price Growth Rating (87) in the Biotechnology industry is in the same range as EKSO (91) in the Medical Specialties industry. This means that GENE’s stock grew similarly to EKSO’s over the last 12 months.
GENE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EKSO (100) in the Medical Specialties industry. This means that GENE’s stock grew similarly to EKSO’s over the last 12 months.
| EKSO | |
|---|---|
| RSI ODDS (%) | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 80% |
| Declines ODDS (%) | 4 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 90% |
EKSO and
Correlation & Price change
A.I.dvisor tells us that EKSO and ATEC have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EKSO and ATEC's prices will move in lockstep.
| Ticker / NAME | Correlation To EKSO | 1D Price Change % | ||
|---|---|---|---|---|
| EKSO | 100% | +0.14% | ||
| ATEC - EKSO | 25% Poorly correlated | +2.82% | ||
| GENE - EKSO | 25% Poorly correlated | N/A | ||
| ICLR - EKSO | 24% Poorly correlated | +4.46% | ||
| MASS - EKSO | 24% Poorly correlated | +7.03% | ||
| CDNA - EKSO | 23% Poorly correlated | +0.94% | ||
More | ||||
GENE and
Correlation & Price change
A.I.dvisor indicates that over the last year, GENE has been loosely correlated with HSCS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GENE jumps, then HSCS could also see price increases.
| Ticker / NAME | Correlation To GENE | 1D Price Change % | ||
|---|---|---|---|---|
| GENE | 100% | N/A | ||
| HSCS - GENE | 46% Loosely correlated | -0.76% | ||
| RSLS - GENE | 45% Loosely correlated | +10.71% | ||
| AXNX - GENE | 32% Poorly correlated | N/A | ||
| INSP - GENE | 31% Poorly correlated | +0.77% | ||
| STAA - GENE | 31% Poorly correlated | +1.18% | ||
More | ||||